The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of Medicine
  • Home
  • Admissions
  • About
    • Strategic Plan
    • Vision & Values
    • Land Acknowledgement
    • Indigenous Health
    • Leadership
    • Academic & Research Units
    • Campuses
    • Facts & Figures
    • Careers
    • Contact
  • News
    • Feature Stories
    • Pathways Magazine
    • The Next Big Question
  • Education
    • Programs
    • Faculty Development
    • Health Education Scholarship
    • Continuing Professional Development
  • Research
    • Priority Areas
    • Canada’s Immuno-Engineering and Biomanufacturing Hub
    • COVID-19 Clinical Research Coordination Initiative
    • Academy of Translational Medicine
    • Edwin S.H. Leong Centre for Healthy Aging
    • Centres & Institutes
    • National Prizes
  • Giving
    • Impact of Giving
    • By the Numbers
    • Ways to Give
    • Webinar Series
    • Contact Us
  • Prospective Students
  • Current Learners
    • Policies & Procedures
    • Respectful Environments, Equity, Diversity & Inclusion
    • Mistreatment Help
    • MD & Undergrad Research
    • Summer Student Research Program
    • Multidisciplinary Research Program in Medicine
    • Grad & Postdoc Education
  • Faculty & Staff
  • Clinical Faculty
    • Becoming Clinical Faculty
    • Appointment Policy & Compensation Terms
    • Teaching Tracking & Payment System
    • Services & Perks
    • Career Development
    • Awards
    • Celebrating Clinical Faculty
    • Advisory Council
    • Contacts
  • Alumni
» Home » News » Alzheimer's researcher reveals a protein's dual destructiveness and therapeutic potential

Contact

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

Alzheimer's researcher reveals a protein's dual destructiveness and therapeutic potential

By bkladko | December 3, 2012

Weihong Song. Photo credit: Martin Dee

A Faculty of Medicine scientist has identified the molecule that controls a scissor-like protein responsible for the production of plaques – the telltale sign of Alzheimer’s disease (AD).

The molecule, known as GSK3-beta, activates a gene that creates the protein, called BACE1. When BACE1 cuts another protein APP, the resulting fragment – known as amyloid beta – forms tiny fibers that clump together into plaques in the brain, eventually killing the neural cells.

Using an animal model of AD, Weihong Song, a Tier 1 Canada Research Chair in Alzheimer’s Disease and professor of psychiatry, found that disabling GSK3-beta’s effect in mice resulted in less BACE1 and far fewer deposits of amyloid in their brains. Dr. Song’s research, published in the Journal of Clinical Investigation, also found that such mice performed  better than untreated mice on memory tests.

Previous research had shown that GSK3-beta spurred the growth of twisted fibers inside neurons, known as tangles – another hallmark of AD. Dr. Song says his discovery of the protein’s dual destructiveness makes it a promising target for drug research.

GSK3-beta, however, is a versatile enzyme that controls many vital physiological functions. The drug used to inhibit GSK3-beta in the mice is too indiscriminate, and could cause several serious side effects, including cancer.

“If we can find a way of stopping GSK3-beta’s specific reaction with BACE1, and still leave it intact to perform other crucial tasks, we have a much better chance of treating AD and preventing its progression,” says Dr. Song, a member of the Brain Research Centre at UBC and the Vancouver Coastal Health Research Institute (VCHRI), and Director of the Townsend Family Laboratories at UBC.

Finding AD therapies is particularly challenging because by the time symptoms of memory loss and cognitive decline appear, much of the damage – in the form of plaques and tangles – has already been done and is irreversible. To demonstrate a preventive effect, a new drug would have to be given to a very large group of people, and those people followed over a long period of time to determine if AD rates are lower than a control group.

Dr. Song conducted some of this research in Chongqing, China, where he is Director of the Canada-China Joint Center for Translational Medical Research in Child Development and Alzheimer’s Disease – a partnership between UBC and the Children’s Hospital of Chongqing Medical University.

Contact Information

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421
Faculty of Medicine
317 - 2194 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 822 2421
Website www.med.ubc.ca
Find us on
    
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility